An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib

摘要

Backgrounds/AimsVitamin K may plays a role in controlling hepatocellular carcinoma (HCC) cell growth. In this study, we intended to present 5-year experience of 72 patients receiving oral vitamin K with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sorafenib and vitamin K.